Combination therapy before and after surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a combination of three drugs (anti-CTLA-4, anti-PD-1, and bevacizumab) before and after surgery can help people with resectable liver cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that can be removed by surgery, and you haven't had any previous treatment for it (or you had surgery or ablation at least 2 years ago).
- You are between 18 and 75 years old.
- Your tumor is larger than 5 cm if single, or you have 2-3 tumors of any size, and the largest is less than 8 cm.
- The cancer has not spread to major blood vessels or other parts of your body.
- You have good liver function (Child-Pugh class A) and are in good overall health (ECOG score 0 or 1).
- You haven't taken any immune therapy drugs (like anti-PD-1 or anti-CTLA-4) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This study tests whether combining two immunotherapy drugs (sintilimab and ipilimumab) with standard procedures to block or destroy the tumor's blood supply can help keep liver cancer from returning after surgery. It is for people whose liver cancer can be removed but has a higher risk of coming back.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
This trial tests a treatment given before surgery to shrink liver cancer and improve outcomes. It combines a liver-directed therapy (HAIC) with two oral drugs (lenvatinib and a PD-1 inhibitor) for people with intermediate-stage liver cancer that can be removed surgically.
Hear when a new Resectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.